--- title: "Clene (CLNN) stock listing, news and investor profile" url: "https://aibio.space/companies/clene/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Clene Inc. (NASDAQ: CLNN), United States. The directory classifies it as Pharmaceuticals: Major." --- CLNN Clene Inc. NASDAQ · United States # Clene (CLNN) news Top story · Oct 20, 2026 · SEC filing 8-K ## [Clene signs a material agreement](https://www.sec.gov/Archives/edgar/data/1822791/000143774926032960/clnn20261012_8k.htm) On October 15, 2026, the Company entered into a subaward amendment for the fourth year of the NIH Grant with NYU for up to $7.2 million during the period from September 1, 2026 to August 31, 2027 (the “Subaward”). Source: [8-K filed Oct 20, 2026 on SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1822791/000143774926032960/clnn20261012_8k.htm) ## Latest Clene news We have not published a story on Clene yet. When there is news, it will appear here. ## Clene at a glance - **Ticker**: CLNN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $9.7 million ### Related companies - [Amylyx Pharmaceuticals](https://aibio.space/companies/amylyx-pharmaceuticals/) NASDAQ: AMLX - [Eledon Pharmaceuticals](https://aibio.space/companies/eledon-pharmaceuticals/) NASDAQ: ELDN - [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) NASDAQ: MPLT - [Lifecore Biomedical](https://aibio.space/companies/lifecore-biomedical/) NASDAQ: LFCR - [LB Pharmaceuticals](https://aibio.space/companies/lb-pharmaceuticals/) NASDAQ: LBRX - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) NASDAQ: AGIO - [Fulcrum Therapeutics](https://aibio.space/companies/fulcrum-therapeutics/) NASDAQ: FULC - [IDEAYA Biosciences](https://aibio.space/companies/ideaya-biosciences/) NASDAQ: IDYA ### Also on NASDAQ - [Dyadic International](https://aibio.space/companies/dyadic-international/) DYAI - [Inogen](https://aibio.space/companies/inogen/) INGN - [Anixa Biosciences](https://aibio.space/companies/anixa-biosciences/) ANIX - [Heartflow](https://aibio.space/companies/heartflow/) HTFL - [Arcutis Biotherapeutics](https://aibio.space/companies/arcutis-biotherapeutics/) ARQT - [BridgeBio Oncology Therapeutics](https://aibio.space/companies/bridgebio-oncology-therapeutics/) BBOT ## Clene annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$200,000](https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/) | [$342,000](https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/) | | Research and development | [$14.0 million](https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/) | [$20.1 million](https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/) | | Net income (loss) | [-$26.2 million](https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/) | [-$39.4 million](https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/) | | Cash from operations | [-$18.5 million](https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/) | [-$21.3 million](https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/) | | Cash and equivalents | [$5.2 million](https://www.sec.gov/Archives/edgar/data/1822791/000143774926027828/) | [$12.2 million](https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/) | | Short-term investments | | [$0](https://www.sec.gov/Archives/edgar/data/1822791/000143774925008956/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Clene What is the ticker symbol of Clene? Clene Inc. trades under the ticker CLNN on NASDAQ. Where is Clene listed? Clene Inc. is listed on NASDAQ. What is the SEC CIK of Clene? The SEC Central Index Key (CIK) for Clene Inc. is 1822791. Its filings are on SEC EDGAR. How many shares does Clene have outstanding? 12,848,513 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Clene listed under? Our directory records Clene Inc. under United States. What does Clene do? Our directory classifies Clene Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Clene? The ISIN recorded for Clene Inc. is US1856342019. Does aibio.space cover Clene? aibio.space lists Clene Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Clene incorporated? SEC records list its state or country of incorporation as DE. What was Clene's revenue last year? $200,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Clene profitable? Clene Inc. reported a net loss of $26.2 million for the fiscal year ended Dec 31, 2025, and used $18.5 million of cash in operations, per its annual report to the SEC. How much does Clene spend on research and development? $14.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Clene have? $9.7 million in cash at Jun 30, 2026, per its 10-Q. What is Clene's market cap? We do not publish live share prices. In its annual report, Clene Inc. put the market value of shares held by non-affiliates (public float) at $40.4 million as of Jun 30, 2025. Is Clene a smaller reporting company? SEC records list Clene Inc.'s filer category as: Non-accelerated filer
Smaller reporting company. ## Investor discussion: Clene Members talk about Clene (CLNN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Clene, newest first. Each line links the filing it comes from. 1. 2026-09-16 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774926030521/clnn20260911_424b5.htm) 2. 2026-05-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774926014935/clnn20260504_424b5.htm) 3. 2026-01-09 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774926000987/clnn20251202_424b5.htm) 4. 2025-10-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774925031275/clnn20251013_424b5.htm) 5. 2025-07-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774925022149/clnn20250701_424b5.htm) 6. 2025-06-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774925020669/clnn20250617_8k.htm) 7. 2025-05-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774925018336/clnn20250521_8k.htm) 8. 2025-05-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774925014917/clnn20250107_8k.htm) 9. 2025-04-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774925013230/clnn20250425_8k.htm) 10. 2025-03-24 Financings Filed a final prospectus for a securities offering. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774925008989/clnn20240815_s3.htm) 11. 2024-12-20 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774924038152/clnn20241217_8k.htm) 12. 2024-12-10 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1822791/000143774924037063/clnn20241028_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CLNN on TradingView](https://www.tradingview.com/symbols/NASDAQ-CLNN/). ## SEC filings and registration - **SEC name**: Clene Inc. - **CIK**: 1822791 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CLNN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121 - **Phone**: 801-676-9695 - **Shares outstanding**: 12,848,513 as of 2026-08-11 (10-Q filed 2026-08-14) - **Former names**: Chelsea Worldwide Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1822791/000143774926032960/clnn20261012_8k.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1822791/000143774926032882/clnn20261019_8k.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1822791/000143774926030581/clnn20260915_8k.htm) filed 2026-09-16 - [424B5](https://www.sec.gov/Archives/edgar/data/1822791/000143774926030521/clnn20260911_424b5.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/clnn20260524_8k.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1822791/000143774926027828/clnn20260630_10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1822791/000143774926026653/clnn20260806_8k.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1822791/000143774926018267/clnn20260514_8k.htm) filed 2026-05-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001822791), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Clene Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CLNN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Clene Inc. - **Ticker**: CLNN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US1856342019 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CLNN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/clene/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Clene (CLNN) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/clene/